Acadia Pharmaceuticals | ACAD - Capital Ordinário





Capital Ordinário Alterar Data
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
ALKERMES USD 166.46M 855K 2026-03
Alnylam Pharmaceuticals USD 133.44M 1.07M 2026-03
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Cara Therapeutics USD 9.38M 9.38M 2025-09
Corcept Therapeutics USD 107.33M 1.36M 2026-03
Cytokinetics USD 124.43M 2.17M 2026-03
Eisai JPY 282.11M 0 2026-03
Eli Lilly USD 943.5M 3.33M 2026-03
Incyte USD 199.95M 1.49M 2026-03
J&J USD 2.41B 1.74M 2025-12
Moderna USD 391M 2M 2025-09
Neurocrine Biosciences USD 100.6M 500K 2026-03
Pfizer USD 5.7B 13M 2026-03
Prothena USD 53.83M 3K 2025-12
PTC Therapeutics USD 81.47M 1.54M 2025-12
Sarepta Therapeutics USD 105.57M 607K 2026-03
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vanda Pharmaceuticals USD 58K 0 2024-12
Vertex Pharmaceuticals USD 254.2M 200K 2026-03